BACKGROUND: Parotid gland squamous cell cancer (SCC) occurs as metastasis from cutaneous SCC or primary malignancy. There is limited data on incidence, prognosis, and treatment outcomes. METHODS: The Surveillance, Epidemiology, and End Results (SEER) database (1988-2009) identified 2104 adult patients with parotid SCC. RESULTS: SCC is the second most common parotid malignancy, and its incidence is increasing (annual percentage change 1.7%; ptrend = .004). Age ≥85 years, tumor size ≥4 cm, extraparenchymal extension, cervical metastases, and distant metastases were independently associated with disease-specific mortality. Compared to no surgery, surgery was associated with improved 5-year disease-specific survival (DSS; 44.4% vs 71.0%; p < .001), whereas radiation alone was similar to no treatment (47.0% vs 41.6%; p = .28). CONCLUSION: Surgery and adjuvant radiation therapy (RT) are associated with improved survival compared to radiation alone and no treatment. Patients ≥85 years of age account for nearly 20% of all patients and have a poor prognosis independent of treatment.
BACKGROUND:Parotid gland squamous cell cancer (SCC) occurs as metastasis from cutaneous SCC or primary malignancy. There is limited data on incidence, prognosis, and treatment outcomes. METHODS: The Surveillance, Epidemiology, and End Results (SEER) database (1988-2009) identified 2104 adult patients with parotid SCC. RESULTS:SCC is the second most common parotid malignancy, and its incidence is increasing (annual percentage change 1.7%; ptrend = .004). Age ≥85 years, tumor size ≥4 cm, extraparenchymal extension, cervical metastases, and distant metastases were independently associated with disease-specific mortality. Compared to no surgery, surgery was associated with improved 5-year disease-specific survival (DSS; 44.4% vs 71.0%; p < .001), whereas radiation alone was similar to no treatment (47.0% vs 41.6%; p = .28). CONCLUSION: Surgery and adjuvant radiation therapy (RT) are associated with improved survival compared to radiation alone and no treatment. Patients ≥85 years of age account for nearly 20% of all patients and have a poor prognosis independent of treatment.
Authors: Orlando Guntinas-Lichius; Thomas G Wendt; Jens Buentzel; Dirk Esser; Daniel Böger; Andreas H Mueller; Jörn-Uwe Piesold; Stefan Schultze-Mosgau; Peter Schlattmann; Harald Schmalenberg Journal: J Cancer Res Clin Oncol Date: 2015-03-24 Impact factor: 4.553
Authors: Hani Z Marzouki; Mohammed A Altabsh; Mohammed O Albakrei; Talal A Al-Khatib; Mazin A Merdad; Nada J Farsi Journal: Saudi Med J Date: 2017-10 Impact factor: 1.484
Authors: Michał Żurek; Kamil Jasak; Karolina Jaros; Piotr Daniel; Kazimierz Niemczyk; Anna Rzepakowska Journal: Int J Environ Res Public Health Date: 2022-08-18 Impact factor: 4.614
Authors: Shira Fishbach; George Steinhardt; Chao Jie Zhen; Rutika Puranik; Jeremy P Segal; Nicole A Cipriani Journal: Head Neck Pathol Date: 2021-06-23
Authors: Antoine Eskander; Jonathan Irish; Jeremy Freeman; Patrick Gullane; Ralph Gilbert; Patti A Groome; Stephen F Hall; David R Urbach; David P Goldstein Journal: J Otolaryngol Head Neck Surg Date: 2014-12-10